[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-001", "question": "A 28-year-old male with a history of opioid use disorder presents with syncope. He admits to taking 'massive doses' of an over-the-counter anti-diarrheal medication to manage withdrawal symptoms. ECG shows sinus bradycardia at 45 bpm, a QTc interval of 680 ms, and intermittent broad-complex beats. He is hemodynamically stable but lethargic. Magnesium sulfate 2g IV is administered without change in the rhythm. Which of the following is the most appropriate next step in management?", "options": ["Option A: IV Amiodarone infusion", "Option B: IV Isoproterenol infusion", "Option C: IV Physostigmine", "Option D: Synchronized cardioversion", "Option E: IV Calcium gluconate"], "answer": "B", "answer_index": 1, "explanation": "The patient has loperamide toxicity, which blocks cardiac sodium and potassium channels, causing QTc prolongation and wide-complex dysrhythmias. Unlike congenital Long QT (where isoproterenol is contraindicated), loperamide-induced TdP/QT prolongation is bradycardia-dependent; increasing the heart rate (chemical or electrical overdrive pacing) shortens the QT interval and prevents Torsades de Pointes. Amiodarone prolongs QT and is contraindicated.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes loperamide toxicity (OTC anti-diarrheal in massive doses for opioid withdrawal) presenting with marked QTc prolongation (680 ms), bradycardia (45 bpm), and broad-complex beats suggesting Torsades de Pointes or ventricular ectopy. Key discriminating findings: hemodynamically stable, bradycardia-dependent QT prolongation, magnesium failed. The clinical problem is preventing/treating loperamide-induced Torsades in a bradycardic patient. Loperamide blocks cardiac sodium and potassium channels, causing acquired Long QT syndrome. Unlike congenital LQTS where isoproterenol may be contraindicated, drug-induced bradycardia-dependent TdP requires heart rate acceleration to shorten QT and suppress arrhythmia. Isoproterenol (Option B) is the correct choice for overdrive pacing when temporary pacing is unavailable. Option A (Amiodarone) is contraindicated as it further prolongs QT. Option C (Physostigmine) treats anticholinergic toxicity, not relevant here. Option D (Cardioversion) is premature in a stable patient; rate acceleration is first-line. Option E (Calcium) treats hyperkalemia/calcium channel blocker toxicity, not indicated. The keyed answer is medically sound and uniquely defensible. No logical flaws or medical inaccuracies. Minimal fix: None needed; item is valid as written.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes loperamide toxicity (OTC anti-diarrheal in massive doses for opioid withdrawal) presenting with marked QTc prolongation (680 ms), bradycardia (45 bpm), and broad-complex beats suggesting Torsades de Pointes or ventricular ectopy. Key discriminating findings: hemodynamically stable, bradycardia-dependent QT prolongation, magnesium failed. The clinical problem is preventing/treating loperamide-induced Torsades in a bradycardic patient. Loperamide blocks cardiac sodium and potassium channels, causing acquired Long QT syndrome. Unlike congenital LQTS where isoproterenol may be contraindicated, drug-induced bradycardia-dependent TdP requires heart rate acceleration to shorten QT and suppress arrhythmia. Isoproterenol (Option B) is the correct choice for overdrive pacing when temporary pacing is unavailable. Option A (Amiodarone) is contraindicated as it further prolongs QT. Option C (Physostigmine) treats anticholinergic toxicity, not relevant here. Option D (Cardioversion) is premature in a stable patient; rate acceleration is first-line. Option E (Calcium) treats hyperkalemia/calcium channel blocker toxicity, not indicated. The keyed answer is medically sound and uniquely defensible. No logical flaws or medical inaccuracies. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-002", "question": "A 4-month-old female presents with failure to thrive, hypotonia, and a history of pyridoxine-responsive seizures. Laboratory evaluation reveals hypercalcemia, hypercalciuria, and a suppressed parathyroid hormone (PTH) level. Skeletal survey demonstrates diffuse demineralization and 'moth-eaten' radiolucencies at the metaphyses. Serum alkaline phosphatase (ALP) is 15 IU/L (Reference: 150-420 IU/L). Which of the following is the definitive treatment for this condition?", "options": ["Option A: High-dose Vitamin D supplementation", "Option B: Recombinant human parathyroid hormone (Teriparatide)", "Option C: Asfotase alfa", "Option D: Pyridoxine (Vitamin B6) monotherapy", "Option E: Bisphosphonate therapy"], "answer": "C", "answer_index": 2, "explanation": "The diagnosis is Hypophosphatasia (HPP), caused by a loss-of-function mutation in the ALPL gene encoding tissue-nonspecific alkaline phosphatase (TNSALP). Low ALP leads to accumulation of inorganic pyrophosphate (an inhibitor of bone mineralization) and pyridoxal-5'-phosphate (causing B6-dependent seizures due to lack of dephosphorylation). Asfotase alfa is the enzyme replacement therapy. Vitamin D and bisphosphonates are contraindicated as they may worsen hypercalcemia and inhibit mineralization further.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 4-month-old with failure to thrive, hypotonia, pyridoxine-responsive seizures, hypercalcemia with suppressed PTH, and critically low serum ALP (15 IU/L, far below reference 150-420). The skeletal survey showing diffuse demineralization and metaphyseal 'moth-eaten' radiolucencies clinches the diagnosis of infantile hypophosphatasia (HPP). Key discriminating findings are the markedly low ALP in the context of skeletal demineralization (paradoxical, since ALP is typically elevated in bone disease) and pyridoxine-responsive seizures (due to accumulation of pyridoxal-5'-phosphate). Asfotase alfa (Option C) is the FDA-approved enzyme replacement therapy for HPP, addressing the underlying TNSALP deficiency. Option A (Vitamin D) is contraindicated due to existing hypercalcemia. Option B (Teriparatide) is not indicated for HPP. Option D (pyridoxine monotherapy) treats seizures symptomatically but not the underlying bone disease. Option E (bisphosphonates) would worsen mineralization by further inhibiting bone turnover. No other option is defensible as definitive treatment. The item is medically accurate, reflects current standard of care, and allows unique best-answer selection. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 4-month-old with failure to thrive, hypotonia, pyridoxine-responsive seizures, hypercalcemia with suppressed PTH, and critically low serum ALP (15 IU/L, far below reference 150-420). The skeletal survey showing diffuse demineralization and metaphyseal 'moth-eaten' radiolucencies clinches the diagnosis of infantile hypophosphatasia (HPP). Key discriminating findings are the markedly low ALP in the context of skeletal demineralization (paradoxical, since ALP is typically elevated in bone disease) and pyridoxine-responsive seizures (due to accumulation of pyridoxal-5'-phosphate). Asfotase alfa (Option C) is the FDA-approved enzyme replacement therapy for HPP, addressing the underlying TNSALP deficiency. Option A (Vitamin D) is contraindicated due to existing hypercalcemia. Option B (Teriparatide) is not indicated for HPP. Option D (pyridoxine monotherapy) treats seizures symptomatically but not the underlying bone disease. Option E (bisphosphonates) would worsen mineralization by further inhibiting bone turnover. No other option is defensible as definitive treatment. The item is medically accurate, reflects current standard of care, and allows unique best-answer selection. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-003", "question": "A 68-year-old male presents with recurrent fevers, painful auricular chondritis, pulmonary infiltrates, and macrocytic anemia. He has been treated for 'refractory relapsing polychondritis' without success. Bone marrow biopsy reveals hypercellularity with prominent cytoplasmic vacuoles in myeloid and erythroid precursor cells. Which of the following is the most likely diagnosis?", "options": ["Option A: Myelodysplastic Syndrome (MDS) with excess blasts", "Option B: VEXAS syndrome", "Option C: Sweet syndrome", "Option D: Polyarteritis Nodosa", "Option E: Granulomatosis with Polyangiitis"], "answer": "B", "answer_index": 1, "explanation": "VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently described disorder caused by somatic mutations in the UBA1 gene. It presents in older men with inflammatory features (chondritis, vasculitis, fevers) and hematologic abnormalities (macrocytic anemia). The pathognomonic finding is vacuoles in myeloid and erythroid precursors in the bone marrow.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 68-year-old male with recurrent fevers, auricular chondritis, pulmonary infiltrates, macrocytic anemia, and refractory 'relapsing polychondritis.' The pathognomonic finding is bone marrow hypercellularity with prominent cytoplasmic vacuoles in myeloid and erythroid precursors. These features—older male, inflammatory manifestations mimicking relapsing polychondritis, macrocytic anemia, and characteristic bone marrow vacuoles—are diagnostic of VEXAS syndrome (Option B). VEXAS is caused by somatic UBA1 mutations and presents with autoinflammatory features plus hematologic abnormalities. Option A (MDS with excess blasts) would not explain the inflammatory features or the specific vacuolated precursors pattern. Option C (Sweet syndrome) lacks bone marrow vacuoles and macrocytic anemia. Options D and E (PAN, GPA) are systemic vasculitides that do not produce the characteristic bone marrow findings or macrocytic anemia. The stem provides sufficient discriminating details (age, sex, inflammatory phenotype, refractory course, pathognomonic marrow findings) to uniquely identify VEXAS. No logical flaws or medical inaccuracies are present. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 68-year-old male with recurrent fevers, auricular chondritis, pulmonary infiltrates, macrocytic anemia, and refractory 'relapsing polychondritis.' The pathognomonic finding is bone marrow hypercellularity with prominent cytoplasmic vacuoles in myeloid and erythroid precursors. These features—older male, inflammatory manifestations mimicking relapsing polychondritis, macrocytic anemia, and characteristic bone marrow vacuoles—are diagnostic of VEXAS syndrome (Option B). VEXAS is caused by somatic UBA1 mutations and presents with autoinflammatory features plus hematologic abnormalities. Option A (MDS with excess blasts) would not explain the inflammatory features or the specific vacuolated precursors pattern. Option C (Sweet syndrome) lacks bone marrow vacuoles and macrocytic anemia. Options D and E (PAN, GPA) are systemic vasculitides that do not produce the characteristic bone marrow findings or macrocytic anemia. The stem provides sufficient discriminating details (age, sex, inflammatory phenotype, refractory course, pathognomonic marrow findings) to uniquely identify VEXAS. No logical flaws or medical inaccuracies are present. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-004", "question": "A 55-year-old female with chronic malnutrition and a history of chronic acetaminophen use for osteoarthritis presents with altered mental status. Arterial blood gas shows pH 7.28, pCO2 28 mmHg, HCO3 12 mEq/L. The anion gap is 24. Lactate is 0.9 mmol/L, serum ketones are negative, and creatinine is 1.1 mg/dL. Toxic alcohol screen is negative. Which of the following is the most appropriate therapeutic intervention?", "options": ["Option A: IV Fomepizole", "Option B: IV Sodium Bicarbonate", "Option C: N-acetylcysteine", "Option D: Hemodialysis", "Option E: Thiamine and Dextrose"], "answer": "C", "answer_index": 2, "explanation": "This patient has high anion gap metabolic acidosis due to 5-oxoproline (pyroglutamic acid) accumulation. This occurs in the setting of glutathione depletion (malnutrition, acetaminophen use), which disrupts the gamma-glutamyl cycle. N-acetylcysteine replenishes glutathione stores, restoring the feedback loop and halting 5-oxoproline production. Fomepizole is for toxic alcohols, which were ruled out.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 55-year-old female with chronic malnutrition and chronic acetaminophen use presenting with high anion gap metabolic acidosis (AG=24, pH 7.28, HCO3 12). Key discriminating findings: (1) chronic acetaminophen use, (2) malnutrition, (3) HAGMA with negative lactate, ketones, and toxic alcohols, (4) normal creatinine ruling out uremia. These clues point to 5-oxoproline (pyroglutamic acid) acidosis, a rare cause of HAGMA in patients with glutathione depletion from malnutrition plus chronic acetaminophen use. The keyed answer (C: N-acetylcysteine) is correct because NAC replenishes glutathione stores, breaking the pathologic cycle. Alternative assessment: (A) Fomepizole is for toxic alcohols—explicitly ruled out; (B) Bicarbonate doesn't address the underlying cause and is not first-line for organic acidoses; (D) Hemodialysis may be considered in severe refractory cases but NAC addresses the root cause; (E) Thiamine/dextrose treats Wernicke's or hypoglycemia, not supported here. The item is medically accurate, representing a classic board-style zebra diagnosis with appropriate clues. No logical flaws or ambiguity. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 55-year-old female with chronic malnutrition and chronic acetaminophen use presenting with high anion gap metabolic acidosis (AG=24, pH 7.28, HCO3 12). Key discriminating findings: (1) chronic acetaminophen use, (2) malnutrition, (3) HAGMA with negative lactate, ketones, and toxic alcohols, (4) normal creatinine ruling out uremia. These clues point to 5-oxoproline (pyroglutamic acid) acidosis, a rare cause of HAGMA in patients with glutathione depletion from malnutrition plus chronic acetaminophen use. The keyed answer (C: N-acetylcysteine) is correct because NAC replenishes glutathione stores, breaking the pathologic cycle. Alternative assessment: (A) Fomepizole is for toxic alcohols—explicitly ruled out; (B) Bicarbonate doesn't address the underlying cause and is not first-line for organic acidoses; (D) Hemodialysis may be considered in severe refractory cases but NAC addresses the root cause; (E) Thiamine/dextrose treats Wernicke's or hypoglycemia, not supported here. The item is medically accurate, representing a classic board-style zebra diagnosis with appropriate clues. No logical flaws or ambiguity. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-005", "question": "A 32-year-old female presents with amenorrhea and galactorrhea. MRI reveals a 4.5 cm pituitary macroadenoma with invasion into the cavernous sinus. Visual fields are intact. Serum prolactin is reported as 145 ng/mL (Reference: <25 ng/mL). Which of the following is the most appropriate next step in management?", "options": ["Option A: Referral for transsphenoidal resection", "Option B: Stereotactic radiosurgery", "Option C: Measurement of prolactin in diluted serum", "Option D: Octreotide scintigraphy", "Option E: Bilateral inferior petrosal sinus sampling"], "answer": "C", "answer_index": 2, "explanation": "A 4.5 cm prolactinoma should typically produce prolactin levels >1,000-10,000 ng/mL. A mildly elevated level in the setting of a giant adenoma suggests the 'Hook Effect,' where excessive antigen saturates the assay antibodies, preventing sandwich formation and leading to a falsely low result. Diluting the sample (1:100) reveals the true elevated value. Confirming a prolactinoma is crucial because dopamine agonists (cabergoline) are the first-line treatment, not surgery.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 32-year-old woman with amenorrhea, galactorrhea, and a 4.5 cm pituitary macroadenoma with cavernous sinus invasion. The key discriminating finding is the discordance between tumor size (4.5 cm, a giant adenoma) and prolactin level (145 ng/mL). Prolactinomas typically produce prolactin proportional to tumor size; a 4.5 cm tumor should yield levels >1,000 ng/mL, often >10,000 ng/mL. This size-prolactin mismatch strongly suggests the hook effect—assay artifact from antigen excess causing falsely low readings. Option C (diluted serum measurement) is the correct next step to unmask the true prolactin level, which would confirm prolactinoma and guide dopamine agonist therapy rather than surgery. Option A (surgery) would be premature without confirming the diagnosis. Option B (radiosurgery) is not first-line for prolactinomas. Option D (octreotide scan) is irrelevant here. Option E (petrosal sampling) is used for ACTH-dependent Cushing's, not prolactinomas. The item is medically accurate, teaching a critical diagnostic pitfall. No logical flaws exist; the stem provides sufficient clues for a unique best answer matching the key. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 32-year-old woman with amenorrhea, galactorrhea, and a 4.5 cm pituitary macroadenoma with cavernous sinus invasion. The key discriminating finding is the discordance between tumor size (4.5 cm, a giant adenoma) and prolactin level (145 ng/mL). Prolactinomas typically produce prolactin proportional to tumor size; a 4.5 cm tumor should yield levels >1,000 ng/mL, often >10,000 ng/mL. This size-prolactin mismatch strongly suggests the hook effect—assay artifact from antigen excess causing falsely low readings. Option C (diluted serum measurement) is the correct next step to unmask the true prolactin level, which would confirm prolactinoma and guide dopamine agonist therapy rather than surgery. Option A (surgery) would be premature without confirming the diagnosis. Option B (radiosurgery) is not first-line for prolactinomas. Option D (octreotide scan) is irrelevant here. Option E (petrosal sampling) is used for ACTH-dependent Cushing's, not prolactinomas. The item is medically accurate, teaching a critical diagnostic pitfall. No logical flaws exist; the stem provides sufficient clues for a unique best answer matching the key. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-006", "question": "A 60-year-old male with a history of radiation therapy for Hodgkin lymphoma presents with signs of cardiac tamponade. Pericardiocentesis is performed, draining 800 mL of bloody fluid. Following drainage, the intrapericardial pressure drops to 0 mmHg, but the right atrial pressure remains elevated at 18 mmHg with a prominent y-descent that was previously absent. Which of the following is the most likely diagnosis?", "options": ["Option A: Incomplete drainage of the effusion", "Option B: Effusive-constrictive pericarditis", "Option C: Right ventricular infarction", "Option D: Pulmonary embolism", "Option E: Flash pulmonary edema"], "answer": "B", "answer_index": 1, "explanation": "Effusive-constrictive pericarditis is characterized by concurrent tamponade and constriction. The visceral pericardium is thickened and constrictive. Initially, the effusion masks the constriction (tamponade physiology: blunted y-descent). After drainage, the tamponade resolves, but the underlying constriction becomes manifest (elevated RA pressure with prominent y-descent). Treatment requires visceral pericardiectomy.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a classic presentation of effusive-constrictive pericarditis in a patient with prior mediastinal radiation (known risk factor). Key discriminating findings: (1) history of radiation therapy, (2) initial tamponade physiology, (3) post-drainage intrapericardial pressure normalizes to 0 mmHg, (4) right atrial pressure remains persistently elevated at 18 mmHg, (5) emergence of prominent y-descent that was absent pre-drainage. The y-descent emergence is pathognomonic—tamponade blunts the y-descent by preventing rapid early diastolic filling; once effusion is drained, the underlying visceral pericardial constriction unmasks, producing the characteristic hemodynamic pattern. Option A (incomplete drainage) is excluded by intrapericardial pressure reaching 0 mmHg. Option C (RV infarction) lacks ischemic context and wouldn't explain the y-descent emergence pattern. Option D (PE) is unsupported by clinical context. Option E (flash pulmonary edema) doesn't explain persistent elevated RA pressure with prominent y-descent. The keyed answer B is medically accurate and uniquely defensible. Minimal fix: None needed; item is well-constructed with appropriate discriminating features and a clear teaching point about post-pericardiocentesis hemodynamics in effusive-constrictive disease.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a classic presentation of effusive-constrictive pericarditis in a patient with prior mediastinal radiation (known risk factor). Key discriminating findings: (1) history of radiation therapy, (2) initial tamponade physiology, (3) post-drainage intrapericardial pressure normalizes to 0 mmHg, (4) right atrial pressure remains persistently elevated at 18 mmHg, (5) emergence of prominent y-descent that was absent pre-drainage. The y-descent emergence is pathognomonic—tamponade blunts the y-descent by preventing rapid early diastolic filling; once effusion is drained, the underlying visceral pericardial constriction unmasks, producing the characteristic hemodynamic pattern. Option A (incomplete drainage) is excluded by intrapericardial pressure reaching 0 mmHg. Option C (RV infarction) lacks ischemic context and wouldn't explain the y-descent emergence pattern. Option D (PE) is unsupported by clinical context. Option E (flash pulmonary edema) doesn't explain persistent elevated RA pressure with prominent y-descent. The keyed answer B is medically accurate and uniquely defensible. Minimal fix: None needed; item is well-constructed with appropriate discriminating features and a clear teaching point about post-pericardiocentesis hemodynamics in effusive-constrictive disease.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-007", "question": "A 65-year-old male is admitted to the ICU for sedation and mechanical ventilation. On day 3 of a continuous propofol infusion, he develops new Right Bundle Branch Block with coved ST-segment elevation in leads V1-V3. Labs reveal severe metabolic acidosis (pH 7.18), Lactate 9 mmol/L, and CK 8,000 U/L. Echocardiogram shows new global hypokinesis. Which of the following is the most likely diagnosis?", "options": ["Option A: Acute Anterior ST-Elevation MI", "Option B: Massive Pulmonary Embolism", "Option C: Propofol Infusion Syndrome", "Option D: Brugada Syndrome unmasked by fever", "Option E: Septic Cardiomyopathy"], "answer": "C", "answer_index": 2, "explanation": "Propofol Infusion Syndrome (PRIS) is a rare but lethal complication of high-dose/long-duration propofol. It causes mitochondrial failure leading to rhabdomyolysis, metabolic acidosis, heart failure, and characteristic ECG changes (often Brugada-like pattern: RBBB with coved ST elevation). Immediate cessation of propofol and supportive care is required.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem provides a classic constellation for Propofol Infusion Syndrome (PRIS): ICU patient on day 3 of continuous propofol infusion developing new RBBB with coved ST-elevation in V1-V3 (Brugada-like pattern), severe metabolic acidosis (pH 7.18), markedly elevated lactate (9 mmol/L), rhabdomyolysis (CK 8,000), and new global hypokinesis. These findings collectively point to mitochondrial dysfunction from propofol toxicity. Option A (Anterior STEMI) is less likely because the ECG pattern described (RBBB with coved ST-elevation V1-V3) is atypical for anterior MI, and the global hypokinesis with severe metabolic acidosis/rhabdomyolysis better fits PRIS. Option B (PE) would not explain the rhabdomyolysis or Brugada-like ECG. Option D (Brugada) requires fever as stated but none is mentioned, and Brugada doesn't cause rhabdomyolysis or this degree of metabolic derangement. Option E (septic cardiomyopathy) lacks supporting infectious signs and doesn't explain the characteristic ECG or rhabdomyolysis. The keyed answer C is uniquely defensible given the temporal relationship to propofol and the pathognomonic triad of metabolic acidosis, rhabdomyolysis, and cardiac dysfunction with Brugada-pattern ECG. Medical accuracy is excellent; PRIS presentation is textbook. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem provides a classic constellation for Propofol Infusion Syndrome (PRIS): ICU patient on day 3 of continuous propofol infusion developing new RBBB with coved ST-elevation in V1-V3 (Brugada-like pattern), severe metabolic acidosis (pH 7.18), markedly elevated lactate (9 mmol/L), rhabdomyolysis (CK 8,000), and new global hypokinesis. These findings collectively point to mitochondrial dysfunction from propofol toxicity. Option A (Anterior STEMI) is less likely because the ECG pattern described (RBBB with coved ST-elevation V1-V3) is atypical for anterior MI, and the global hypokinesis with severe metabolic acidosis/rhabdomyolysis better fits PRIS. Option B (PE) would not explain the rhabdomyolysis or Brugada-like ECG. Option D (Brugada) requires fever as stated but none is mentioned, and Brugada doesn't cause rhabdomyolysis or this degree of metabolic derangement. Option E (septic cardiomyopathy) lacks supporting infectious signs and doesn't explain the characteristic ECG or rhabdomyolysis. The keyed answer C is uniquely defensible given the temporal relationship to propofol and the pathognomonic triad of metabolic acidosis, rhabdomyolysis, and cardiac dysfunction with Brugada-pattern ECG. Medical accuracy is excellent; PRIS presentation is textbook. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-008", "question": "A 58-year-old male with dyslipidemia develops proximal muscle weakness and myalgias. His CK is 8,500 U/L. Atorvastatin is discontinued. Two months later, his weakness has progressed, and CK remains elevated at 9,200 U/L. Muscle biopsy shows necrotizing myopathy with minimal inflammation. Testing for anti-HMGCR antibodies is positive. Which of the following is the most appropriate management?", "options": ["Option A: Switch to Rosuvastatin", "Option B: Initiate Coenzyme Q10 supplementation", "Option C: Initiate IVIG and/or systemic immunosuppression", "Option D: Observation for spontaneous resolution", "Option E: Dantrolene sodium"], "answer": "C", "answer_index": 2, "explanation": "This patient has Statin-Associated Autoimmune Myopathy (SAAM), specifically anti-HMGCR positive necrotizing myopathy. Unlike self-limited statin myotoxicity, this is an autoimmune process that progresses despite statin cessation. It requires aggressive immunosuppression (steroids, IVIG, Rituximab, or Methotrexate) to prevent permanent muscle loss.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 58-year-old male with statin-associated necrotizing myopathy that persists and progresses despite discontinuation of atorvastatin. Key discriminating findings include: (1) proximal muscle weakness and myalgias on statin therapy, (2) markedly elevated CK (8,500→9,200 U/L), (3) progression after statin discontinuation, (4) muscle biopsy showing necrotizing myopathy with minimal inflammation, and (5) positive anti-HMGCR antibodies. These findings establish statin-associated autoimmune myopathy (SAAM), an immune-mediated necrotizing myopathy that requires immunosuppressive therapy. Option C (IVIG and/or systemic immunosuppression) is the established treatment. Option A (switching statins) would worsen the condition. Option B (CoQ10) lacks evidence for autoimmune myopathy. Option D (observation) would allow progressive muscle damage. Option E (dantrolene) treats malignant hyperthermia, not autoimmune myopathy. The keyed answer is medically accurate and represents standard care for anti-HMGCR myopathy. The stem provides sufficient detail to identify a unique best answer. No logical flaws or medical inaccuracies present. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 58-year-old male with statin-associated necrotizing myopathy that persists and progresses despite discontinuation of atorvastatin. Key discriminating findings include: (1) proximal muscle weakness and myalgias on statin therapy, (2) markedly elevated CK (8,500→9,200 U/L), (3) progression after statin discontinuation, (4) muscle biopsy showing necrotizing myopathy with minimal inflammation, and (5) positive anti-HMGCR antibodies. These findings establish statin-associated autoimmune myopathy (SAAM), an immune-mediated necrotizing myopathy that requires immunosuppressive therapy. Option C (IVIG and/or systemic immunosuppression) is the established treatment. Option A (switching statins) would worsen the condition. Option B (CoQ10) lacks evidence for autoimmune myopathy. Option D (observation) would allow progressive muscle damage. Option E (dantrolene) treats malignant hyperthermia, not autoimmune myopathy. The keyed answer is medically accurate and represents standard care for anti-HMGCR myopathy. The stem provides sufficient detail to identify a unique best answer. No logical flaws or medical inaccuracies present. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-009", "question": "A 2-week-old XX infant presents with ambiguous genitalia (virilization). Vital signs reveal a blood pressure of 96/60 mmHg (hypertensive for age). Laboratory evaluation shows Sodium 136 mEq/L and Potassium 2.9 mEq/L. 17-hydroxyprogesterone is elevated. Which of the following enzyme deficiencies is the most likely cause?", "options": ["Option A: 21-hydroxylase deficiency", "Option B: 11-beta-hydroxylase deficiency", "Option C: 17-alpha-hydroxylase deficiency", "Option D: 3-beta-hydroxysteroid dehydrogenase deficiency", "Option E: P450 oxidoreductase deficiency"], "answer": "B", "answer_index": 1, "explanation": "Congenital Adrenal Hyperplasia due to 11-beta-hydroxylase deficiency blocks cortisol synthesis, shunting precursors to androgens (causing virilization in females) and accumulating 11-deoxycorticosterone (DOC). DOC is a potent mineralocorticoid, leading to salt retention, hypertension, and hypokalemia. This distinguishes it from the more common 21-hydroxylase deficiency, which causes salt-wasting (hypotension, hyperkalemia).", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: The keyed answer (B, 11β-hydroxylase deficiency) is incorrect; the correct answer is A (21-hydroxylase deficiency). Key stem clues: 2-week-old XX infant with virilization, elevated 17-hydroxyprogesterone (17-OHP), hypertension, and hypokalemia. Main logical issue: The stem states 17-OHP is elevated, which is the pathognomonic finding for 21-hydroxylase deficiency, NOT 11β-hydroxylase deficiency. In 11β-hydroxylase deficiency, 11-deoxycortisol and DOC accumulate (causing hypertension and hypokalemia), but 17-OHP is typically normal or only mildly elevated. The dramatically elevated 17-OHP specifically indicates 21-hydroxylase deficiency. While the hypertension and hypokalemia pattern fits 11β-hydroxylase deficiency, the explicit mention of elevated 17-OHP overrides this and points definitively to 21-hydroxylase deficiency. The item contains contradictory biochemical information: elevated 17-OHP (diagnostic of 21-hydroxylase) combined with hypertension/hypokalemia (typical of 11β-hydroxylase). This creates internal inconsistency. Minimal fix: Either remove the 17-OHP finding and keep answer B, or change the electrolyte/BP pattern to hyponatremia/hyperkalemia/hypotension and keep 17-OHP elevated with answer A.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer (B, 11β-hydroxylase deficiency) is incorrect; the correct answer is A (21-hydroxylase deficiency). Key stem clues: 2-week-old XX infant with virilization, elevated 17-hydroxyprogesterone (17-OHP), hypertension, and hypokalemia. Main logical issue: The stem states 17-OHP is elevated, which is the pathognomonic finding for 21-hydroxylase deficiency, NOT 11β-hydroxylase deficiency. In 11β-hydroxylase deficiency, 11-deoxycortisol and DOC accumulate (causing hypertension and hypokalemia), but 17-OHP is typically normal or only mildly elevated. The dramatically elevated 17-OHP specifically indicates 21-hydroxylase deficiency. While the hypertension and hypokalemia pattern fits 11β-hydroxylase deficiency, the explicit mention of elevated 17-OHP overrides this and points definitively to 21-hydroxylase deficiency. The item contains contradictory biochemical information: elevated 17-OHP (diagnostic of 21-hydroxylase) combined with hypertension/hypokalemia (typical of 11β-hydroxylase). This creates internal inconsistency. Minimal fix: Either remove the 17-OHP finding and keep answer B, or change the electrolyte/BP pattern to hyponatremia/hyperkalemia/hypotension and keep 17-OHP elevated with answer A.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-010", "question": "A 45-year-old male on chronic amiodarone therapy for atrial fibrillation presents with weight loss and palpitations. TSH is <0.01 mIU/L and Free T4 is elevated. He has no neck pain. Thyroid ultrasound with color flow Doppler reveals an absence of vascularity within the thyroid parenchyma. Which of the following is the most appropriate initial treatment?", "options": ["Option A: Methimazole", "Option B: Propylthiouracil", "Option C: Prednisone", "Option D: Radioactive Iodine ablation", "Option E: Potassium Perchlorate"], "answer": "C", "answer_index": 2, "explanation": "This is Type 2 Amiodarone-Induced Thyrotoxicosis (AIT), which is a destructive thyroiditis caused by direct cytotoxic effects of the drug. The key differentiator from Type 1 AIT (Jod-Basedow/iodine-induced synthesis) is the Doppler flow: Type 1 has increased vascularity, while Type 2 has absent vascularity. Type 2 is treated with high-dose glucocorticoids. Thionamides (Methimazole) are ineffective for destructive thyroiditis.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict on keyed answer: Correct best. The vignette describes a patient on chronic amiodarone presenting with thyrotoxicosis (suppressed TSH, elevated Free T4). The critical discriminating finding is the Doppler ultrasound showing absent thyroid vascularity, which definitively distinguishes Type 2 amiodarone-induced thyrotoxicosis (AIT) from Type 1. Type 2 AIT is a destructive thyroiditis caused by direct cytotoxic effects of amiodarone, releasing preformed thyroid hormone. The absence of vascularity excludes Type 1 AIT (which shows increased vascularity due to iodine-induced hypersynthesis). Prednisone (Option C) is the correct initial treatment for Type 2 AIT, as glucocorticoids reduce inflammation and hormone release from the destructive process. Methimazole and PTU (Options A, B) block hormone synthesis and are ineffective in destructive thyroiditis where preformed hormone is being released. Radioactive iodine (Option D) is contraindicated in destructive thyroiditis due to low uptake. Potassium perchlorate (Option E) blocks iodine uptake and is used for Type 1 AIT or mixed cases, not pure Type 2. The stem provides sufficient discriminating information (Doppler findings) to identify a unique best answer. Medical accuracy is excellent; the item reflects current understanding of AIT classification and management. No fix needed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The vignette describes a patient on chronic amiodarone presenting with thyrotoxicosis (suppressed TSH, elevated Free T4). The critical discriminating finding is the Doppler ultrasound showing absent thyroid vascularity, which definitively distinguishes Type 2 amiodarone-induced thyrotoxicosis (AIT) from Type 1. Type 2 AIT is a destructive thyroiditis caused by direct cytotoxic effects of amiodarone, releasing preformed thyroid hormone. The absence of vascularity excludes Type 1 AIT (which shows increased vascularity due to iodine-induced hypersynthesis). Prednisone (Option C) is the correct initial treatment for Type 2 AIT, as glucocorticoids reduce inflammation and hormone release from the destructive process. Methimazole and PTU (Options A, B) block hormone synthesis and are ineffective in destructive thyroiditis where preformed hormone is being released. Radioactive iodine (Option D) is contraindicated in destructive thyroiditis due to low uptake. Potassium perchlorate (Option E) blocks iodine uptake and is used for Type 1 AIT or mixed cases, not pure Type 2. The stem provides sufficient discriminating information (Doppler findings) to identify a unique best answer. Medical accuracy is excellent; the item reflects current understanding of AIT classification and management. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]